Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (317) 317
tiotropium (317) 317
index medicus (271) 271
pulmonary disease, chronic obstructive - drug therapy (266) 266
respiratory system (217) 217
male (210) 210
female (204) 204
copd (201) 201
lung diseases, obstructive (189) 189
tiotropium bromide (180) 180
middle aged (178) 178
chronic obstructive pulmonary disease (176) 176
aged (169) 169
obstructive pulmonary-disease (165) 165
administration, inhalation (158) 158
bronchodilator agents - therapeutic use (150) 150
treatment outcome (148) 148
bronchodilator agents - administration & dosage (145) 145
pulmonary disease, chronic obstructive - physiopathology (137) 137
drug therapy (122) 122
bronchodilator agents - adverse effects (116) 116
scopolamine derivatives - therapeutic use (108) 108
double-blind method (105) 105
efficacy (93) 93
pharmacology & pharmacy (87) 87
care and treatment (85) 85
safety (84) 84
respiratory tract diseases (83) 83
salmeterol (81) 81
pulmonary disease, chronic obstructive - diagnosis (79) 79
asthma (78) 78
research (78) 78
dosage and administration (77) 77
forced expiratory volume (76) 76
scopolamine derivatives - administration & dosage (76) 76
mortality (75) 75
drug therapy, combination (68) 68
exacerbations (68) 68
adult (65) 65
original research (64) 64
quality of life (63) 63
tiotropium bromide - administration & dosage (63) 63
clinical trials (61) 61
diseases of the respiratory system (61) 61
lung-function (60) 60
lung - physiopathology (59) 59
severity of illness index (58) 58
scopolamine derivatives - adverse effects (57) 57
time factors (56) 56
forced expiratory volume - drug effects (55) 55
muscarinic antagonists - administration & dosage (55) 55
analysis (54) 54
lung - drug effects (53) 53
spirometry (53) 53
pulmonary and respiratory medicine (51) 51
pulmonary/respiratory (51) 51
muscarinic antagonists - adverse effects (50) 50
formoterol (45) 45
respiratory agents (45) 45
muscarinic antagonists - therapeutic use (44) 44
aged, 80 and over (43) 43
drug administration schedule (43) 43
drug combinations (43) 43
nebulizers and vaporizers (43) 43
respimat (43) 43
tiotropium bromide - adverse effects (43) 43
cross-over studies (41) 41
international journal of chronic obstructive pulmonary disease (41) 41
double-blind (40) 40
bronchodilators (39) 39
adrenergic beta-2 receptor agonists - administration & dosage (38) 38
asthma - drug therapy (38) 38
therapy (38) 38
bronchodilator (37) 37
studies (37) 37
cardiac & cardiovascular systems (36) 36
patients (36) 36
review (36) 36
tiotropium bromide - therapeutic use (36) 36
adrenergic beta-2 receptor agonists - therapeutic use (35) 35
cholinergic antagonists - administration & dosage (35) 35
risk factors (35) 35
dyspnea (34) 34
indacaterol (34) 34
medicine & public health (34) 34
trial (34) 34
cholinergic antagonists - therapeutic use (33) 33
disease progression (33) 33
health aspects (33) 33
risk (33) 33
usage (33) 33
drug dosages (32) 32
internal medicine (32) 32
albuterol - analogs & derivatives (31) 31
cholinergic antagonists - adverse effects (31) 31
complications and side effects (31) 31
medicine, general & internal (31) 31
adrenergic beta-2 receptor agonists - adverse effects (30) 30
albuterol - therapeutic use (30) 30
combination (30) 30
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Tiotropium handihaler® and respimat®in copd: A pooled safety analysis
by Halpin, David M. G and Dahl, Ronald and Hallmann, Christoph and Mueller, Achim and Tashkin, Donald
International Journal of COPD, ISSN 1176-9106, 02/2015, Volume 10, pp. 239 - 259
Introduction: Tiotropium is prescribed for the treatment of chronic obstructive pulmonary disease (COPD) and delivered via HandiHaler (R) (18 mu g once daily)... 
HandiHaler | Tiotropium | Respimat | EFFICACY | CARDIOVASCULAR EVENTS | AIR-FLOW | EXERCISE TOLERANCE | Respimat (R) | tiotropium | ONCE-DAILY TIOTROPIUM | OBSTRUCTIVE PULMONARY-DISEASE | HandiHaler (R) | RESPIRATORY SYSTEM | EXACERBATIONS | INHALATION POWDER | INHALED ANTICHOLINERGICS | HEALTH OUTCOMES | Pulmonary Disease, Chronic Obstructive - mortality | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Equipment Design | Forced Expiratory Volume | Time Factors | Patient Safety | Scopolamine Derivatives - administration & dosage | Female | Bronchodilator Agents - adverse effects | Odds Ratio | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Pulmonary Disease, Chronic Obstructive - diagnosis | Risk Factors | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Randomized Controlled Trials as Topic | Muscarinic Antagonists - administration & dosage | Vital Capacity | Lung - drug effects | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Clinical trials | Complications and side effects | Lung diseases, Obstructive | Management | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Patients' perspectives and preferences in the choice of inhalers: the case for Respimat((R)) or HandiHaler((R))
by Dekhuijzen, P.N.R and Lavorini, F and Usmani, O.S
Patient Preference and Adherence, ISSN 1177-889X, 2016, Volume 10, pp. 1561 - 1572
Poor inhaler technique hampers the efficacy of drug therapy in asthma and chronic obstructive pulmonary disease. Not only does this affect individual patient... 
Chronic obstructive pulmonary disease | Tiotropium Respimat | Soft Mist™ Inhaler | Inhaler technique | Tiotropium HandiHaler | Asthma | PULMONARY DRUG-DELIVERY | MANAGEMENT | INHALATION DEVICES | GUIDELINES | Soft Mist (TM) Inhaler | inhaler technique | asthma | CARE | SOFT MIST(TM) INHALER | AEROSOL THERAPY | MEDICINE, GENERAL & INTERNAL | tiotropium HandiHaler (R) | METERED-DOSE INHALERS | chronic obstructive pulmonary disease | tiotropium Respimat (R) | COPD | Respiratory agents | Care and treatment | Drug therapy | Patients | Patient compliance | tiotropium HandiHaler | tiotropium Respimat
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Tiotropium Respimat® vs. HandiHaler®: real‐life usage and TIOSPIR trial generalizability
by Schmiedl, Sven and Fischer, Rainald and Ibanez, Luisa and Fortuny, Joan and Thürmann, Petra and Ballarin, Elena and Ferrer, Pili and Sabaté, Monica and Rottenkolber, Dominik and Gerlach, Roman and Tauscher, Martin and Reynolds, Robert and Hasford, Joerg and Rottenkolber, Marietta
British Journal of Clinical Pharmacology, ISSN 0306-5251, 02/2016, Volume 81, Issue 2, pp. 379 - 388
Aim Two inhaler devices (Respimat® and HandiHaler®) are available for tiotropium, a long acting anticholinergic agent. We aimed to analyze drug utilization,... 
real‐life usage | TIOSPIR trial | secondary data analysis | COPD | tiotropium | real-life usage | MORTALITY | RANDOMIZED CONTROLLED-TRIALS | POPULATION | METAANALYSIS | INHALER DEVICES | RISK | PRACTITIONERS | OBSTRUCTIVE PULMONARY-DISEASE | ASTHMA | PHARMACOLOGY & PHARMACY | COPD PATIENTS | Dry Powder Inhalers | Humans | Administration, Inhalation | Male | Clinical Trials as Topic | Cholinergic Antagonists - administration & dosage | Tiotropium Bromide - administration & dosage | Metered Dose Inhalers | Female | Tiotropium Bromide - therapeutic use | Aged | Cholinergic Antagonists - therapeutic use | Drug Utilization - statistics & numerical data | Off-Label Use - statistics & numerical data | Databases, Factual | Pulmonary Disease, Chronic Obstructive - drug therapy | Usage | Lung diseases, Obstructive | Information management | Index Medicus | Pharmacoepidemiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and safety of combining olodaterol Respimat® and tiotropium HandiHaler® in patients with COPD: Results of two randomized, double-blind, active-controlled studies
by ZuWallack, Richard and Allen, Lisa and Hernandez, Gemzel and Ting, Naitee and Abrahams, Roger
International Journal of COPD, ISSN 1176-9106, 10/2014, Volume 9, pp. 1133 - 1144
Background: Combining bronchodilators with different mechanisms of action may improve efficacy and reduce risk of side effects compared to increasing the dose... 
Olodaterol Respimat | Long-acting muscarinic antagonist | Bronchodilator | Long-acting beta2-agonist | Tiotropium HandiHaler | INDACATEROL | TRIALS | OBSTRUCTIVE PULMONARY-DISEASE | MANAGEMENT | long-acting beta2-agonist | RESPIRATORY SYSTEM | tiotropium HandiHaler (R) | long-acting muscarinic antagonist | bronchodilator | olodaterol Respimat (R) | Spirometry | Bronchodilator Agents - administration & dosage | United States | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Equipment Design | Forced Expiratory Volume | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Scopolamine Derivatives - administration & dosage | Female | Surveys and Questionnaires | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Pulmonary Disease, Chronic Obstructive - diagnosis | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Benzoxazines - adverse effects | Treatment Outcome | Lung - physiopathology | Muscarinic Antagonists - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium | Lung diseases, Obstructive | Research | Drug therapy, Combination | Drug therapy | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text The efficacy of tiotropium administered via Respimat (R) Soft MistT (TM) Inhaler or HandiHaler (R) in COPD patients
by van Noord, JA and Cornelissen, PJG and Aumann, JL and Platz, J and Mueller, A and Fogarty, C
RESPIRATORY MEDICINE, ISSN 0954-6111, 01/2009, Volume 103, Issue 1, pp. 22 - 29
Background: Tiotropium, a once daily inhaled anticholinergic delivered via HandiHaler (R), provides bronchodilation for >24 h and improves patient-centred... 
CARDIAC & CARDIOVASCULAR SYSTEMS | Inhalation therapy | SAFETY | PERFORMANCE | LUNG-FUNCTION | EXERCISE TOLERANCE | Respimat (R) | COMBINATION | SALMETEROL | ONCE-DAILY TIOTROPIUM | Anticholinergics | Tiotropium | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | Bronchodilators | Chronic obstructive pulmonary disease | FLUTICASONE | HEALTH OUTCOMES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Comparison of peak inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry powder inhalers in patients with moderate to very severe COPD: A randomized cross-over trial
by Altman, Pablo and Wehbe, Luis and Dederichs, Juergen and Guerin, Tadhg and Ament, Brian and Moronta, Miguel Cardenas and Pino, Andrea Valeria and Goyal, Pankaj
BMC Pulmonary Medicine, ISSN 1471-2466, 06/2018, Volume 18, Issue 1, pp. 100 - 8
Background: The chronic and progressive nature of chronic obstructive pulmonary disease (COPD) requires self-administration of inhaled medication. Dry powder... 
Dry powder inhalers | Peak inspiratory flow | Pressure drop | Breezhaler | Inspiratory effort | OBSTRUCTIVE PULMONARY-DISEASE | Breezhaler (R) | DRUG-DELIVERY | RESPIRATORY SYSTEM | DELIVERY CHARACTERISTICS | RESISTANCE | DEVICES | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Age Factors | Outcome Assessment (Health Care) | Humans | Middle Aged | Respiratory Therapy - methods | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Airway Resistance | Equipment Design | Respiratory Therapy - instrumentation | Cross-Over Studies | Pulmonary Disease, Chronic Obstructive - therapy | Self Administration - methods | Dry Powder Inhalers - instrumentation | Smoking - physiopathology | Sex Factors | Work of Breathing | Female | Self Administration - instrumentation | Aged | Inspiratory Capacity | Dry Powder Inhalers - methods | Respiratory therapy | Tiotropium | Lung diseases, Obstructive | Care and treatment | Usage | Indacaterol | Dosage and administration | Comparative analysis | Inhalers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: Does inhaler choice matter?
by Dahl, Ronald and Kaplan, Alan
BMC Pulmonary Medicine, ISSN 1471-2466, 10/2016, Volume 16, Issue 1, p. 135
Background: In many countries worldwide, the long-acting anticholinergic drug tiotropium is available as a dry powder formulation delivered by means of the... 
Chronic obstructive pulmonary disease | Tiotropium Respimat | Soft Mist™ Inhaler | Tiotropium HandiHaler | Tiotropium HandiHaler (R) | MORTALITY | CARDIAC SAFETY | EFFICACY | PERFORMANCE | DEPOSITION | Soft Mist (TM) Inhaler | TIOSPIR(TM) SAFETY | Tiotropium Respimat (R) | SOFT MIST(TM) INHALER | AEROSOL | RESPIRATORY SYSTEM | POWDER | COPD | Forced Expiratory Volume | Tiotropium Bromide - administration & dosage | Bronchodilator Agents - administration & dosage | Humans | Administration, Inhalation | Metered Dose Inhalers | Lung - physiopathology | Patient Preference | Pulmonary Disease, Chronic Obstructive - physiopathology | Pulmonary Disease, Chronic Obstructive - drug therapy | Randomized Controlled Trials as Topic | Drugs | Tiotropium | Drug delivery systems | Usage | Lung diseases, Obstructive | Care and treatment | Physicians | Practice | Dosage and administration | Drug therapy | Vehicles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Tiotropium Respimat® Versus HandiHaler®: Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials
by Calverley, Peter M. A and Könen-Bergmann, Michael and Richard, Frank and Bell, Susan and Hohlfeld, Jens M
Advances in Therapy, ISSN 0741-238X, 5/2016, Volume 33, Issue 5, pp. 786 - 793
The long-acting muscarinic antagonist tiotropium bromide is approved in many countries as maintenance therapy for chronic obstructive pulmonary disease (COPD).... 
Pulmonology | Chronic obstructive pulmonary disease (COPD) | Spirometry | Dose–response | Long-acting muscarinic antagonist | Bronchodilator | Rheumatology | Internal Medicine | Oncology | Efficacy | Respimat | Tiotropium | Lung function | Medicine & Public Health | Once-daily | Cardiology | Pharmacology/Toxicology | Endocrinology | MEDICINE, RESEARCH & EXPERIMENTAL | SAFETY | PERFORMANCE | Respimat (R) | INHALER | OBSTRUCTIVE PULMONARY-DISEASE | TIOSPIR(R) | Dose-response | PHARMACOLOGY & PHARMACY | COPD PATIENTS | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Tiotropium Bromide - adverse effects | Administration, Inhalation | Male | Treatment Outcome | Muscarinic Antagonists - therapeutic use | Tiotropium Bromide - pharmacokinetics | Dose-Response Relationship, Drug | Tiotropium Bromide - administration & dosage | Bronchodilator Agents - pharmacokinetics | Female | Aged | Bronchodilator Agents - adverse effects | Drug Monitoring | Pulmonary Disease, Chronic Obstructive - drug therapy | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effect of Switching Tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in Patients with COPD: The Difference of Adverse Events and Usability Between Inhaler Devices
by Asakura, Yuka and Nishimura, Naoki and Maezawa, Kayoko and Terajima, Tomoko and Kizu, Junko and Chohnabayashi, Naohiko
Journal of Aerosol Medicine and Pulmonary Drug Delivery, ISSN 1941-2711, 02/2013, Volume 26, Issue 1, pp. 41 - 45
Background: Recently, tiotropium Respimat ® Soft Mist ™ Inhaler has been developed. Respimat is a multidose and propellant-free kit. The aerosol generated from... 
Original Research | HandiHaler | Respimat | chronic obstructive pulmonary disease (COPD) | tiotropium | HandiHaler (R) | EFFICACY | Respimat (R) | RESPIRATORY SYSTEM | Prospective Studies | Bronchodilator Agents - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Administration, Inhalation | Male | Dyspnea - etiology | Equipment Design | Dyspnea - epidemiology | Forced Expiratory Volume | Cough - etiology | Scopolamine Derivatives - administration & dosage | Aged, 80 and over | Aged | Xerostomia - etiology | Bronchodilator Agents - adverse effects | Xerostomia - epidemiology | Scopolamine Derivatives - therapeutic use | Nebulizers and Vaporizers | Scopolamine Derivatives - adverse effects | Cohort Studies | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Bronchodilator efficacy of 18 mu g once-daily tiotropium inhalation via Discair (R) versus HandiHaler (R) in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial
by Yildiz, P and Bayraktaroglu, M and Gorgun, D and Secik, F
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ISSN 1178-2005, 2016, Volume 11, pp. 2859 - 2867
Purpose: To compare the bronchodilator efficacy of 18 mu g once-daily tiotropium inhalation administered via Discair (R) versus HandiHaler (R) in adults with... 
MANAGEMENT | non-inferiority | Discair (R) | INHALER DEVICES | ADHERENCE | tiotropium | bronchodilator efficacy | IMPACT | spirometry | HandiHaler (R) | RESPIRATORY SYSTEM | ASTHMA | PATIENT | POWDER | COPD PATIENTS | RESPIMAT | HEALTH OUTCOMES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Assessment of patient performance of the HandiHaler ® compared with the metered dose inhaler four weeks after instruction
by Dahl, R and Backer, V and Ollgaard, B and Gerken, F and Kesten, S
Respiratory Medicine, ISSN 0954-6111, 2003, Volume 97, Issue 10, pp. 1126 - 1133
The HandiHaler® is a novel breath-actuated dry powder system designed for the delivery of tiotropium 18 μg daily in the treatment of COPD. We compared patient... 
Tiotropium | Chronic obstructive pulmonary disease | Performance | Inhaler technique | Device | Bronchodilator | CARDIAC & CARDIOVASCULAR SYSTEMS | performance | RESPIRATORY SYSTEM | KNOWLEDGE | inhaler technique | POWDER | device | bronchodilator | chronic obstructive pulmonary disease | tiotropium | DELIVERY | COPD | Single-Blind Method | Age Factors | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Patient Participation | Administration, Inhalation | Male | Treatment Outcome | Nebulizers and Vaporizers - standards | Scopolamine Derivatives - administration & dosage | Sex Factors | Aged, 80 and over | Metered Dose Inhalers | Adult | Female | Aged | Patient Education as Topic | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Respiratory therapy | Drug dosages | Evacuations & rescues
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial
by Dahl, Ronald and Calverley, Peter M A and Anzueto, Antonio and Metzdorf, Norbert and Fowler, Andy and Mueller, Achim and Wise, Robert and Dusser, Daniel
BMJ Open, ISSN 2044-6055, 12/2015, Volume 5, Issue 12, p. e009015
ObjectivesThis post hoc analysis of TIOtropium Safety and Performance In Respimat (TIOSPIR) evaluated safety and exacerbation efficacy in patients with stable... 
MORTALITY | RANDOMIZED CONTROLLED-TRIALS | METAANALYSIS | Efficacy | RISK | Respimat (R) | Switching | Tiotropium | MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | HandiHaler (R) | CLINICAL-TRIALS | POWDER | MIST INHALER | COPD | Pulmonary Disease, Chronic Obstructive - mortality | Bronchodilator Agents - administration & dosage | Double-Blind Method | Humans | Middle Aged | Risk Factors | Tiotropium Bromide - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Administration, Inhalation | Male | Treatment Outcome | International Cooperation | Equipment Design | Disease Progression | Forced Expiratory Volume | Tiotropium Bromide - administration & dosage | Female | Aged | Bronchodilator Agents - adverse effects | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Cardiac safety of tiotropium in patients with cardiac events: A retrospective analysis of the UPLIFT® trial
by Tashkin, Donald P and Leimer, Inge and Metzdorf, Norbert and Decramer, Marc
Respiratory Research, ISSN 1465-9921, 06/2015, Volume 16, Issue 1, p. 65
Background: Tiotropium is an anticholinergic bronchodilator for symptom relief and reducing exacerbations with an established safety profile in patients with... 
UPLIFT | Cardiac safety | Tiotropium HandiHaler | COPD | Tiotropium HandiHaler (R) | MORTALITY | UPLIFT (R) | METAANALYSIS | EFFICACY | RISK | SOFT MIST(TM) INHALER | OBSTRUCTIVE PULMONARY-DISEASE | AEROSOL | HANDIHALER | RESPIRATORY SYSTEM | RESPIMAT | Bronchodilator Agents - therapeutic use | Pulmonary Disease, Chronic Obstructive - mortality | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Humans | Tiotropium Bromide - adverse effects | Male | Mortality - trends | Cardiovascular Diseases - mortality | Female | Tiotropium Bromide - therapeutic use | Cardiovascular Diseases - chemically induced | Retrospective Studies | Bronchodilator Agents - adverse effects | Cardiovascular Diseases - diagnosis | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Analysis | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationale
by Wise, Robert A and Anzueto, Antonio and Calverley, Peter and Dahl, Ronald and Dusser, Daniel and Pledger, Gordon and Koenen-Bergmann, Michael and Joseph, Elizabeth and Cotton, Daniel and Disse, Bernd
Respiratory Research, ISSN 1465-9921, 04/2013, Volume 14, Issue 1, pp. 40 - 40
Background: Tiotropium bromide is an effective therapy for COPD patients. Comparing across programs tiotropium Respimat (R) Soft Mist T inhaler was at least as... 
HandiHaler | Tiotropium | Respimat® Soft Mist™ Inhaler | COPD | OBSTRUCTIVE PULMONARY-DISEASE | METAANALYSIS | HandiHaler (R) | EFFICACY | RESPIRATORY SYSTEM | Soft Mist (TM) Inhaler | Respimat (R) | COPD PATIENTS | INHALER | Prevalence | Bronchodilator Agents - administration & dosage | Humans | Risk Factors | Administration, Inhalation | Male | Treatment Outcome | Pulmonary Disease, Chronic Obstructive - epidemiology | Internationality | Metered Dose Inhalers - utilization | Scopolamine Derivatives - administration & dosage | Female | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Care and treatment | Lung diseases, Obstructive | Epidemiology | Cardiac patients | Marketing | Studies | Clinical trials | Chronic obstructive pulmonary disease | Heart attacks | Pharmaceutical industry | Mortality | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study
by Jahnz-Różyk, Karina and Szepiel, Paweł
International Journal of COPD, ISSN 1176-9106, 05/2015, Volume 10, pp. 613 - 623
Background: Long-acting inhaled bronchodilators, including anticholinergic tiotropium, are recommended for the maintenance therapy of chronic obstructive... 
Spiriva ® HandiHaler | Chronic obstructive pulmonary disease | GOLD classification | CAT | Spiriva (R) HandiHaler (R) | RESPIRATORY SYSTEM | chronic obstructive pulmonary disease | SALMETEROL | Bronchodilator Agents - therapeutic use | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Prospective Studies | Humans | Middle Aged | Tiotropium Bromide - adverse effects | Male | Treatment Outcome | Lung - physiopathology | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Time Factors | Lung - drug effects | Poland | Product Surveillance, Postmarketing | Female | Tiotropium Bromide - therapeutic use | Aged | Bronchodilator Agents - adverse effects | Health Status | Cholinergic Antagonists - adverse effects | Cholinergic Antagonists - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium | Lung diseases, Obstructive | Drug therapy | Patient outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Safety of inhaled long-acting anti-muscarinic agents in COPD
by Hanania, Nicola A and Lareau, Suzanne C and Yawn, Barbara P
Postgraduate Medicine, ISSN 0032-5481, 07/2017, Volume 129, Issue 5, pp. 500 - 512
Evidence-based guidelines recommend inhaled long-acting anti-muscarinic agents (LAMAs) as first-line maintenance therapy for symptomatic patients with COPD.... 
aclidinium | Chronic obstructive pulmonary disease (COPD) | long-acting anti-muscarinics (LAMA) | umeclidinium | safety | glycopyrronium | tiotropium | IMPROVES LUNG-FUNCTION | PHARMACOLOGICAL CHARACTERIZATION | INDIVIDUAL COMPONENTS | TIOTROPIUM HANDIHALER(R) | ONCE-DAILY NVA237 | MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE | TO-SEVERE COPD | DOUBLE-BLIND | FIXED-DOSE COMBINATION | Administration, Inhalation | Muscarinic Antagonists - administration & dosage | Muscarinic Antagonists - therapeutic use | Humans | Patient Safety | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in central and eastern Europe
by Fležar, Matjaž and Jahnz-Rózyk, Karina and Enache, Gloria and Martynenko, Tatiana and Kristufek, Peter and Škrinjarić-Cincar, Sanda and Kadlecová, Pavla and Martinovic, Goran
International Journal of COPD, ISSN 1176-9106, 10/2013, Volume 8, pp. 483 - 492
Purpose: The long-acting inhaled anticholinergic agent, tiotropium, is recommended as first-line maintenance therapy for moderate to very severe Chronic... 
HandiHaler | Health-related quality of life | Tiotropium | Chronic obstructive pulmonary disease | TRIAL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | HandiHaler (R) | EFFICACY | RESPIRATORY SYSTEM | health-related quality of life | QUALITY-OF-LIFE | tiotropium | chronic obstructive pulmonary disease | HEALTH-STATUS | COPD | Bronchodilator Agents - therapeutic use | Europe, Eastern | Multivariate Analysis | Predictive Value of Tests | Prospective Studies | Age Factors | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Recovery of Function | Time Factors | Scopolamine Derivatives - administration & dosage | Product Surveillance, Postmarketing | Female | Surveys and Questionnaires | Scopolamine Derivatives - therapeutic use | Cholinergic Antagonists - therapeutic use | Tiotropium Bromide | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Drug Administration Schedule | Risk Factors | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Cholinergic Antagonists - administration & dosage | Medication Adherence | Lung - drug effects | Aged | Health Status | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine | Lung diseases, Obstructive | Analysis | Practice | Respiratory agents | Drug therapy | Health aspects | Quality management | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients
by Price, David and Sharma, Ashish and Cerasoli, Frank
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 04/2009, Volume 5, Issue 4, pp. 417 - 424
Background: Chronic obstructive pulmonary disease (COPD) is a progressive disease with increasing incidence and mortality. Tiotropium is an inhaled long-acting... 
pharmacokinetics | metabolism | HRQL | FEV | tiotropium | FEV1 | Tiotropium | Metabolism | Pharmacokinetics | BRONCHODILATOR | MORTALITY | SYSTEM | BIOCHEMISTRY & MOLECULAR BIOLOGY | HANDIHALER(R) | INHALER | PROFILE | IPRATROPIUM | PHARMACOLOGY & PHARMACY | HOSPITALIZATIONS | TOXICOLOGY | LUNG HEALTH | COPD | Scopolamine Derivatives - pharmacology | Humans | Administration, Inhalation | Bronchodilator Agents - pharmacology | Receptors, Muscarinic - metabolism | Scopolamine Derivatives - chemistry | Bronchodilator Agents - chemistry | Animals | Bronchodilator Agents - pharmacokinetics | Protein Binding - drug effects | Pulmonary Disease, Chronic Obstructive - metabolism | Scopolamine Derivatives - pharmacokinetics | Protein Binding - physiology | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Tiotropium 5 mu g via Respimat and 18 mu g via HandiHaler; efficacy and safety in Japanese COPD patients
by Ichinose, M and Fujimoto, T and Fukuchi, Y
RESPIRATORY MEDICINE, ISSN 0954-6111, 02/2010, Volume 104, Issue 2, pp. 228 - 236
Background and objectives: To compare the efficacy and safety of tiotropium inhaled via Respimat(R) Soft Mist Inhaler, a multidose propellant-free inhaler and... 
BRONCHODILATOR | LUNG | CARDIAC & CARDIOVASCULAR SYSTEMS | PERFORMANCE | EXERCISE TOLERANCE | SOFT MIST(TM) INHALER | TRIAL | Tiotropium | OBSTRUCTIVE PULMONARY-DISEASE | IPRATROPIUM | RESPIRATORY SYSTEM | Bronchodilators | EXACERBATIONS | Inhalation devices | Pharmacokinetics | COPD | HEALTH OUTCOMES
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study
by Spila-Alegiani, Stefania and Trotta, Francesco and Da Cas, Roberto and Rossi, Mariangela and Venegoni, Mauro and Traversa, Giuseppe
COPD: Journal of Chronic Obstructive Pulmonary Disease, ISSN 1541-2555, 09/2018, Volume 15, Issue 5, pp. 418 - 423
The effectiveness of the tiotropium Respimat ® formulation in routine clinical practice is still an open issue due to concern about the generalizability of the... 
Tiotropium | HandiHaler | cohort study | chronic obstructive pulmonary disease (COPD) | comparative effectiveness | Respimat | real-world data | RESPIRATORY SYSTEM | INCLUSION | INHALER
Journal Article